Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen
- Author
- JOHNSON, John R1 ; COHEN, Martin1 ; LI SHAN HSIEH1 ; CHIDAMBARAM, Nallalerumal1 ; ZIMMERMAN, Paul1 ; PAZDUR, Richard1 ; SRIDHARA, Rajeshwari1 ; CHEN, Yeh-Fong1 ; WILLIAMS, Gene M1 ; DUAN, John1 ; GOBBURU, Jogarao1 ; BOOTH, Brian1 ; BENSON, Kimberly1 ; LEIGHTON, John1
[1] Division of Oncology Drug Products (HFD-150) Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Maryland, United States - Source
Clinical cancer research. 2005, Vol 11, Num 18, pp 6414-6421, 8 p ; ref : 14 ref
- ISSN
- 1078-0432
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- American Association for Cancer Research, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Cancer du poumon Carcinome non petite cellule bronchopulmonaire Chimiothérapie Erlotinib Homme Métastase Stade avancé Traitement Appareil respiratoire pathologie Bronche pathologie Enzyme Inhibiteur enzyme Poumon pathologie Protein-tyrosine kinase Récepteur facteur croissance épiderme Transferases Tumeur maligne
- Keyword (en)
- Antineoplastic agent Lung cancer non-small cell lung carcinoma Chemotherapy Erlotinib Human Metastasis Advanced stage Treatment Respiratory disease Bronchus disease Enzyme Enzyme inhibitor Lung disease Protein-tyrosine kinase Epidermal growth factor receptor Transferases Malignant tumor
- Keyword (es)
- Anticanceroso Cáncer del pulmón Carcinoma no pequeňa célula bronchopulmonar Quimioterapia Erlotinib Hombre Metástasis Estadio avanzado Tratamiento Aparato respiratorio patología Bronquio patología Enzima Inhibidor enzima Pulmón patología Protein-tyrosine kinase Receptor factor crecimiento epidermi Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B11 Pneumology / 002B11A Tumors of the respiratory system and mediastinum
- Discipline
- Pharmacological treatments Pulmonology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17118272
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1158/1078-0432.CCR-05-0790 
https://dx.doi.org/10.1158/1078-0432.CCR-05-0790
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-05-0790\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:2:\"18\";s:8:\"\u0000*\u0000spage\";s:4:\"6414\";s:8:\"\u0000*\u0000epage\";s:4:\"6421\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"JOHNSON\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:13:\"COHEN, Martin\";i:1;s:13:\"LI SHAN HSIEH\";i:2;s:25:\"CHIDAMBARAM, Nallalerumal\";i:3;s:15:\"ZIMMERMAN, Paul\";i:4;s:15:\"PAZDUR, Richard\";i:5;s:20:\"SRIDHARA, Rajeshwari\";i:6;s:14:\"CHEN, Yeh-Fong\";i:7;s:16:\"WILLIAMS, Gene M\";i:8;s:10:\"DUAN, John\";i:9;s:16:\"GOBBURU, Jogarao\";i:10;s:12:\"BOOTH, Brian\";i:11;s:16:\"BENSON, Kimberly\";i:12;s:14:\"LEIGHTON, John\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:176:\"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-05-0790\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:2:\"18\";s:8:\"\u0000*\u0000spage\";s:4:\"6414\";s:8:\"\u0000*\u0000epage\";s:4:\"6421\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"JOHNSON\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:13:\"COHEN, Martin\";i:1;s:13:\"LI SHAN HSIEH\";i:2;s:25:\"CHIDAMBARAM, Nallalerumal\";i:3;s:15:\"ZIMMERMAN, Paul\";i:4;s:15:\"PAZDUR, Richard\";i:5;s:20:\"SRIDHARA, Rajeshwari\";i:6;s:14:\"CHEN, Yeh-Fong\";i:7;s:16:\"WILLIAMS, Gene M\";i:8;s:10:\"DUAN, John\";i:9;s:16:\"GOBBURU, Jogarao\";i:10;s:12:\"BOOTH, Brian\";i:11;s:16:\"BENSON, Kimberly\";i:12;s:14:\"LEIGHTON, John\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:176:\"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-05-0790\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-05-0790\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:2:\"18\";s:8:\"\u0000*\u0000spage\";s:4:\"6414\";s:8:\"\u0000*\u0000epage\";s:4:\"6421\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"JOHNSON\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:13:\"COHEN, Martin\";i:1;s:13:\"LI SHAN HSIEH\";i:2;s:25:\"CHIDAMBARAM, Nallalerumal\";i:3;s:15:\"ZIMMERMAN, Paul\";i:4;s:15:\"PAZDUR, Richard\";i:5;s:20:\"SRIDHARA, Rajeshwari\";i:6;s:14:\"CHEN, Yeh-Fong\";i:7;s:16:\"WILLIAMS, Gene M\";i:8;s:10:\"DUAN, John\";i:9;s:16:\"GOBBURU, Jogarao\";i:10;s:12:\"BOOTH, Brian\";i:11;s:16:\"BENSON, Kimberly\";i:12;s:14:\"LEIGHTON, John\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:176:\"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-05-0790\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:2:\"18\";s:8:\"\u0000*\u0000spage\";s:4:\"6414\";s:8:\"\u0000*\u0000epage\";s:4:\"6421\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"JOHNSON\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:13:\"COHEN, Martin\";i:1;s:13:\"LI SHAN HSIEH\";i:2;s:25:\"CHIDAMBARAM, Nallalerumal\";i:3;s:15:\"ZIMMERMAN, Paul\";i:4;s:15:\"PAZDUR, Richard\";i:5;s:20:\"SRIDHARA, Rajeshwari\";i:6;s:14:\"CHEN, Yeh-Fong\";i:7;s:16:\"WILLIAMS, Gene M\";i:8;s:10:\"DUAN, John\";i:9;s:16:\"GOBBURU, Jogarao\";i:10;s:12:\"BOOTH, Brian\";i:11;s:16:\"BENSON, Kimberly\";i:12;s:14:\"LEIGHTON, John\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:176:\"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-05-0790\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"11\";s:8:\"\u0000*\u0000issue\";s:2:\"18\";s:8:\"\u0000*\u0000spage\";s:4:\"6414\";s:8:\"\u0000*\u0000epage\";s:4:\"6421\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"JOHNSON\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:13:\"COHEN, Martin\";i:1;s:13:\"LI SHAN HSIEH\";i:2;s:25:\"CHIDAMBARAM, Nallalerumal\";i:3;s:15:\"ZIMMERMAN, Paul\";i:4;s:15:\"PAZDUR, Richard\";i:5;s:20:\"SRIDHARA, Rajeshwari\";i:6;s:14:\"CHEN, Yeh-Fong\";i:7;s:16:\"WILLIAMS, Gene M\";i:8;s:10:\"DUAN, John\";i:9;s:16:\"GOBBURU, Jogarao\";i:10;s:12:\"BOOTH, Brian\";i:11;s:16:\"BENSON, Kimberly\";i:12;s:14:\"LEIGHTON, John\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:176:\"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
